Information for Semaglutide
Semaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.
Research Certificates of Analysis
12.07mg
Task #42392
Batch #04302024
05/08/2024
10.27mg
Task #42384
Batch #04082024
04/12/2024
10.49mg
Task #42386
Batch #04102024
04/16/2024
5.66mg
Task #42243
Batch #05172024
05/17/2024
GMP Certificates of Analysis
5mg
Batch #PKSEM05924
09/10/2024
10.5mg
Batch #PKSEM10924
09/10/2024
Semaglutide Peptide Structure
Sequence: HXEGTFTSDVSSYLEGQAAK-OH.steric diacid-EFIAWLVRGRG
Molecular Formula: C187H291N45O59
Molecular Weight: 4113.64 g/mol
PubChem CID: 56843331
CAS Number: 910463-68-2
Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535
What Is Semaglutide?
Regulates blood glucose levels1
Reduces body weight1
Shows promise in cardioprotective treatment2
May suppress hunger and food cravings3
Delays gastric emptying4
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2017). Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial. Diabetes Care, 41(2), 258–266. https://doi.org/10.2337/dc17-0417
- Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. Diabetes & Endocrinology, 7(10), 776–785. https://doi.org/10.1016/s2213-8587(19)30249-9
- Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932
- Urva, S., O’Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023b). The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 25(9), 2784–2788. https://doi.org/10.1111/dom.15167
Product Usage
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
